Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Sales (2021 - 2025)

InMed Pharmaceuticals' Return on Sales history spans 5 years, with the latest figure at 2.47% for Q4 2025.

  • For Q4 2025, Return on Sales fell 16.0% year-over-year to 2.47%; the TTM value through Dec 2025 reached 1.7%, down 6.0%, while the annual FY2025 figure was 1.65%, 2.0% up from the prior year.
  • Return on Sales reached 2.47% in Q4 2025 per INM's latest filing, down from 1.54% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.15% in Q2 2023 to a low of 16.16% in Q4 2021.
  • Average Return on Sales over 5 years is 4.58%, with a median of 1.93% recorded in 2023.
  • Peak YoY movement for Return on Sales: skyrocketed 1514bps in 2023, then crashed -136bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 16.16% in 2021, then soared by 72bps to 4.47% in 2022, then surged by 73bps to 1.19% in 2023, then crashed by -94bps to 2.32% in 2024, then dropped by -7bps to 2.47% in 2025.
  • Per Business Quant, the three most recent readings for INM's Return on Sales are 2.47% (Q4 2025), 1.54% (Q3 2025), and 1.37% (Q2 2025).